Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000823214 | SCV000964065 | pathogenic | not provided | 2022-02-03 | criteria provided, single submitter | clinical testing | This sequence change affects the initiator methionine of the CERKL mRNA. The next in-frame methionine is located at codon 206. This variant is not present in population databases (gnomAD no frequency). Disruption of the initiator codon has been observed in individual(s) with CERKL-related disease (Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 665011). This variant disrupts a region of the CERKL protein in which other variant(s) (p.Cys125Trp) have been determined to be pathogenic (PMID: 20554613, 24498393, 29068140). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV001277038 | SCV005655350 | pathogenic | Retinitis pigmentosa 26 | 2024-04-15 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001277038 | SCV001463773 | likely pathogenic | Retinitis pigmentosa 26 | 2020-09-16 | no assertion criteria provided | clinical testing |